{"id":67950,"date":"2024-07-31T13:10:42","date_gmt":"2024-07-31T17:10:42","guid":{"rendered":"https:\/\/www.med.unc.edu\/medicine\/?p=67950"},"modified":"2024-07-31T13:32:36","modified_gmt":"2024-07-31T17:32:36","slug":"unc-hematology-and-lineberger-staff-published-a-study-on-anti-cd30-car-t-cell-therapy-in-high-risk-lymphoma-patients","status":"publish","type":"post","link":"https:\/\/www.med.unc.edu\/medicine\/news\/unc-hematology-and-lineberger-staff-published-a-study-on-anti-cd30-car-t-cell-therapy-in-high-risk-lymphoma-patients\/","title":{"rendered":"ºÚÁÏÍø Hematology and Lineberger Faculty Published a Study on Anti-CD30 CAR T-Cell Therapy in High-Risk Lymphoma Patients"},"content":{"rendered":"

This new study highlights safety and efficacy of Anti-CD30 CAR T-Cell therapy in high-risk lymphoma patients<\/em><\/p>\n

\n

A team comprised mainly of faculty from the Division of Hematology and ºÚÁÏÍø Lineberger Comprehensive Cancer Center published a groundbreaking phase 1 study in <\/span>The Lancet Haematology<\/span><\/a>. <\/span><\/i>The study demonstrates the safety and promising activity of anti-CD30 CAR T cells as consolidation therapy after autologous haematopoietic stem-cell transplantation (HSCT) in patients with high-risk CD30+ lymphoma, primarily Hodgkin lymphoma.<\/span><\/p>\n

Their study offers significant hope for patients with relapsed high risk Hodgkin lymphoma, demonstrating that anti-CD30 CAR T-cell therapy can be safely administered as a consolidation treatment following autologous haematopoietic stem-cell transplantation. The therapy showed promising preliminary activity with manageable side effects and no treatment-related deaths, suggesting a potential new avenue for reducing relapse rates and improving long-term outcomes in these patients<\/span><\/p>\n

The study included 21 patients, 18 of whom received the CAR T-cell infusion after HSCT. The treatment was well-tolerated with no dose-limiting toxicities, and the highest dose of 2 \u00d7 10^8 CAR T cells per m^2 was established as the maximum tolerated dose.<\/span><\/p>\n

The most common grade 3-4 adverse events were lymphopenia and leukopenia, observed in two patients each. No treatment-related deaths occurred. With a median follow-up of 48.2 months, the median progression-free survival for all treated patients was 32.3 months, showing promising activity. The study concludes that anti-CD30 CAR T-cell therapy given after autologous stem cell transplant is safe and suggests the need for larger studies to further validate these findings<\/span><\/p>\n

Further large-scale studies are needed to confirm these encouraging results and potentially establish a new standard of care for high-risk lymphoma patients.<\/span><\/p>\n

The esteemed team features; Natalie S. Grover MD, George Hucks MD, Marcie L. Riches MD, Anastasia Ivanova PhD, Dominic T Moore MPH, Thomas C Shea MD, Mary Beth Seegars MD, Paul M Armistead MD PhD, Kimberly A Kasow DO, Anne W. Beaven MD, Christopher Dittus DO, James M Coghill MD, Katarzyna J Jamieson MD, Benjamin G Vincent MD, William A Wood MD, Catherine Cheng CCPS, Julia Kaitlin Morrison PhD, John West PhD, Tammy Cavallo BS, Gianpietro Dotti MD, Jonathan S Serody MD, and Barbara Savoldo MD PhD.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"

This new study highlights safety and efficacy of Anti-CD30 CAR T-Cell therapy in high-risk lymphoma patients A team comprised mainly of faculty from the Division of Hematology and ºÚÁÏÍø Lineberger Comprehensive Cancer Center published a groundbreaking phase 1 study in The Lancet Haematology. The study demonstrates the safety and promising activity of anti-CD30 CAR T … Read more<\/a><\/p>\n","protected":false},"author":116983,"featured_media":3663,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"layout":"","cellInformation":"","apiCallInformation":"","footnotes":"","_links_to":"","_links_to_target":""},"categories":[520,92,583],"tags":[],"class_list":["post-67950","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-hematology","category-research","category-research-news","odd"],"acf":[],"yoast_head":"\nºÚÁÏÍø Hematology and Lineberger Faculty Published a Study on Anti-CD30 CAR T-Cell Therapy in High-Risk Lymphoma Patients | Department of Medicine<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.med.unc.edu\/medicine\/news\/unc-hematology-and-lineberger-staff-published-a-study-on-anti-cd30-car-t-cell-therapy-in-high-risk-lymphoma-patients\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ºÚÁÏÍø Hematology and Lineberger Faculty Published a Study on Anti-CD30 CAR T-Cell Therapy in High-Risk Lymphoma Patients | Department of Medicine\" \/>\n<meta property=\"og:description\" content=\"This new study highlights safety and efficacy of Anti-CD30 CAR T-Cell therapy in high-risk lymphoma patients A team comprised mainly of faculty from the Division of Hematology and ºÚÁÏÍø Lineberger Comprehensive Cancer Center published a groundbreaking phase 1 study in The Lancet Haematology. The study demonstrates the safety and promising activity of anti-CD30 CAR T … Read more\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.med.unc.edu\/medicine\/news\/unc-hematology-and-lineberger-staff-published-a-study-on-anti-cd30-car-t-cell-therapy-in-high-risk-lymphoma-patients\/\" \/>\n<meta property=\"og:site_name\" content=\"Department of Medicine\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ºÚÁÏÍøDeptMedicine\" \/>\n<meta property=\"article:published_time\" content=\"2024-07-31T17:10:42+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-07-31T17:32:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2018\/12\/macnider.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1000\" \/>\n\t<meta property=\"og:image:height\" content=\"580\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Lillian Harbison\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@uncdeptmedicine\" \/>\n<meta name=\"twitter:site\" content=\"@uncdeptmedicine\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Lillian Harbison\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/news\/unc-hematology-and-lineberger-staff-published-a-study-on-anti-cd30-car-t-cell-therapy-in-high-risk-lymphoma-patients\/\",\"url\":\"https:\/\/www.med.unc.edu\/medicine\/news\/unc-hematology-and-lineberger-staff-published-a-study-on-anti-cd30-car-t-cell-therapy-in-high-risk-lymphoma-patients\/\",\"name\":\"ºÚÁÏÍø Hematology and Lineberger Faculty Published a Study on Anti-CD30 CAR T-Cell Therapy in High-Risk Lymphoma Patients | Department of Medicine\",\"isPartOf\":{\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/news\/unc-hematology-and-lineberger-staff-published-a-study-on-anti-cd30-car-t-cell-therapy-in-high-risk-lymphoma-patients\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/news\/unc-hematology-and-lineberger-staff-published-a-study-on-anti-cd30-car-t-cell-therapy-in-high-risk-lymphoma-patients\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2018\/12\/macnider.png\",\"datePublished\":\"2024-07-31T17:10:42+00:00\",\"dateModified\":\"2024-07-31T17:32:36+00:00\",\"author\":{\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/#\/schema\/person\/583f230c1448c20a7f8507f25c34980c\"},\"breadcrumb\":{\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/news\/unc-hematology-and-lineberger-staff-published-a-study-on-anti-cd30-car-t-cell-therapy-in-high-risk-lymphoma-patients\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.med.unc.edu\/medicine\/news\/unc-hematology-and-lineberger-staff-published-a-study-on-anti-cd30-car-t-cell-therapy-in-high-risk-lymphoma-patients\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/news\/unc-hematology-and-lineberger-staff-published-a-study-on-anti-cd30-car-t-cell-therapy-in-high-risk-lymphoma-patients\/#primaryimage\",\"url\":\"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2018\/12\/macnider.png\",\"contentUrl\":\"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2018\/12\/macnider.png\",\"width\":1000,\"height\":580,\"caption\":\"MacNider Building\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/news\/unc-hematology-and-lineberger-staff-published-a-study-on-anti-cd30-car-t-cell-therapy-in-high-risk-lymphoma-patients\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.med.unc.edu\/medicine\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ºÚÁÏÍø Hematology and Lineberger Faculty Published a Study on Anti-CD30 CAR T-Cell Therapy in High-Risk Lymphoma Patients\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/#website\",\"url\":\"https:\/\/www.med.unc.edu\/medicine\/\",\"name\":\"Department of Medicine\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.med.unc.edu\/medicine\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/#\/schema\/person\/583f230c1448c20a7f8507f25c34980c\",\"name\":\"Lillian Harbison\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.med.unc.edu\/medicine\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/1876faa809b17d5109176b637c5bbd78?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/1876faa809b17d5109176b637c5bbd78?s=96&d=mm&r=g\",\"caption\":\"Lillian Harbison\"},\"url\":\"https:\/\/www.med.unc.edu\/medicine\/news\/author\/lilharbi\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ºÚÁÏÍø Hematology and Lineberger Faculty Published a Study on Anti-CD30 CAR T-Cell Therapy in High-Risk Lymphoma Patients | Department of Medicine","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.med.unc.edu\/medicine\/news\/unc-hematology-and-lineberger-staff-published-a-study-on-anti-cd30-car-t-cell-therapy-in-high-risk-lymphoma-patients\/","og_locale":"en_US","og_type":"article","og_title":"ºÚÁÏÍø Hematology and Lineberger Faculty Published a Study on Anti-CD30 CAR T-Cell Therapy in High-Risk Lymphoma Patients | Department of Medicine","og_description":"This new study highlights safety and efficacy of Anti-CD30 CAR T-Cell therapy in high-risk lymphoma patients A team comprised mainly of faculty from the Division of Hematology and ºÚÁÏÍø Lineberger Comprehensive Cancer Center published a groundbreaking phase 1 study in The Lancet Haematology. The study demonstrates the safety and promising activity of anti-CD30 CAR T … Read more","og_url":"https:\/\/www.med.unc.edu\/medicine\/news\/unc-hematology-and-lineberger-staff-published-a-study-on-anti-cd30-car-t-cell-therapy-in-high-risk-lymphoma-patients\/","og_site_name":"Department of Medicine","article_publisher":"https:\/\/www.facebook.com\/ºÚÁÏÍøDeptMedicine","article_published_time":"2024-07-31T17:10:42+00:00","article_modified_time":"2024-07-31T17:32:36+00:00","og_image":[{"width":1000,"height":580,"url":"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2018\/12\/macnider.png","type":"image\/png"}],"author":"Lillian Harbison","twitter_card":"summary_large_image","twitter_creator":"@uncdeptmedicine","twitter_site":"@uncdeptmedicine","twitter_misc":{"Written by":"Lillian Harbison","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.med.unc.edu\/medicine\/news\/unc-hematology-and-lineberger-staff-published-a-study-on-anti-cd30-car-t-cell-therapy-in-high-risk-lymphoma-patients\/","url":"https:\/\/www.med.unc.edu\/medicine\/news\/unc-hematology-and-lineberger-staff-published-a-study-on-anti-cd30-car-t-cell-therapy-in-high-risk-lymphoma-patients\/","name":"ºÚÁÏÍø Hematology and Lineberger Faculty Published a Study on Anti-CD30 CAR T-Cell Therapy in High-Risk Lymphoma Patients | Department of Medicine","isPartOf":{"@id":"https:\/\/www.med.unc.edu\/medicine\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.med.unc.edu\/medicine\/news\/unc-hematology-and-lineberger-staff-published-a-study-on-anti-cd30-car-t-cell-therapy-in-high-risk-lymphoma-patients\/#primaryimage"},"image":{"@id":"https:\/\/www.med.unc.edu\/medicine\/news\/unc-hematology-and-lineberger-staff-published-a-study-on-anti-cd30-car-t-cell-therapy-in-high-risk-lymphoma-patients\/#primaryimage"},"thumbnailUrl":"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2018\/12\/macnider.png","datePublished":"2024-07-31T17:10:42+00:00","dateModified":"2024-07-31T17:32:36+00:00","author":{"@id":"https:\/\/www.med.unc.edu\/medicine\/#\/schema\/person\/583f230c1448c20a7f8507f25c34980c"},"breadcrumb":{"@id":"https:\/\/www.med.unc.edu\/medicine\/news\/unc-hematology-and-lineberger-staff-published-a-study-on-anti-cd30-car-t-cell-therapy-in-high-risk-lymphoma-patients\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.med.unc.edu\/medicine\/news\/unc-hematology-and-lineberger-staff-published-a-study-on-anti-cd30-car-t-cell-therapy-in-high-risk-lymphoma-patients\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.med.unc.edu\/medicine\/news\/unc-hematology-and-lineberger-staff-published-a-study-on-anti-cd30-car-t-cell-therapy-in-high-risk-lymphoma-patients\/#primaryimage","url":"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2018\/12\/macnider.png","contentUrl":"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2018\/12\/macnider.png","width":1000,"height":580,"caption":"MacNider Building"},{"@type":"BreadcrumbList","@id":"https:\/\/www.med.unc.edu\/medicine\/news\/unc-hematology-and-lineberger-staff-published-a-study-on-anti-cd30-car-t-cell-therapy-in-high-risk-lymphoma-patients\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.med.unc.edu\/medicine\/"},{"@type":"ListItem","position":2,"name":"ºÚÁÏÍø Hematology and Lineberger Faculty Published a Study on Anti-CD30 CAR T-Cell Therapy in High-Risk Lymphoma Patients"}]},{"@type":"WebSite","@id":"https:\/\/www.med.unc.edu\/medicine\/#website","url":"https:\/\/www.med.unc.edu\/medicine\/","name":"Department of Medicine","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.med.unc.edu\/medicine\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.med.unc.edu\/medicine\/#\/schema\/person\/583f230c1448c20a7f8507f25c34980c","name":"Lillian Harbison","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.med.unc.edu\/medicine\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/1876faa809b17d5109176b637c5bbd78?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1876faa809b17d5109176b637c5bbd78?s=96&d=mm&r=g","caption":"Lillian Harbison"},"url":"https:\/\/www.med.unc.edu\/medicine\/news\/author\/lilharbi\/"}]}},"featured_image":"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2018\/12\/macnider.png","featured_image_medium":"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2018\/12\/macnider-300x174.png","featured_image_medium_large":"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2018\/12\/macnider-768x445.png","featured_image_large":"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2018\/12\/macnider.png","featured_image_thumbnail":"https:\/\/www.med.unc.edu\/medicine\/wp-content\/uploads\/sites\/945\/2018\/12\/macnider-150x150.png","featured_image_alt":"MacNider Building","category_details":[{"name":"Hematology","link":"https:\/\/www.med.unc.edu\/medicine\/news\/category\/hematology\/"},{"name":"Research","link":"https:\/\/www.med.unc.edu\/medicine\/news\/category\/research\/"},{"name":"Research News","link":"https:\/\/www.med.unc.edu\/medicine\/news\/category\/research-news\/"}],"tag_details":[],"_links_to":[],"_links_to_target":[],"_links":{"self":[{"href":"https:\/\/www.med.unc.edu\/medicine\/wp-json\/wp\/v2\/posts\/67950","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.med.unc.edu\/medicine\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.med.unc.edu\/medicine\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.med.unc.edu\/medicine\/wp-json\/wp\/v2\/users\/116983"}],"replies":[{"embeddable":true,"href":"https:\/\/www.med.unc.edu\/medicine\/wp-json\/wp\/v2\/comments?post=67950"}],"version-history":[{"count":2,"href":"https:\/\/www.med.unc.edu\/medicine\/wp-json\/wp\/v2\/posts\/67950\/revisions"}],"predecessor-version":[{"id":67953,"href":"https:\/\/www.med.unc.edu\/medicine\/wp-json\/wp\/v2\/posts\/67950\/revisions\/67953"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.med.unc.edu\/medicine\/wp-json\/wp\/v2\/media\/3663"}],"wp:attachment":[{"href":"https:\/\/www.med.unc.edu\/medicine\/wp-json\/wp\/v2\/media?parent=67950"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.med.unc.edu\/medicine\/wp-json\/wp\/v2\/categories?post=67950"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.med.unc.edu\/medicine\/wp-json\/wp\/v2\/tags?post=67950"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}